FDA and state rules, for what you actually buy.

Must a pharmacy located in another state hold a license/registration from this state to ship prescriptions (including patient-specific 503A compounded preparations) to patients or practitioners here?

Fla. Stat. §465.0156 treats any out-of-state pharmacy that ships, mails or delivers a dispensed medicinal drug into Florida as a nonresident pharmacy that must register with the Board (biennial renewal). It must disclose its home-state license, officers and prescription department manager, keep Florida records readily retrievable, and provide a toll-free line (at least 6 days and 40 hours a week). The pharmacy and its prescription department manager must be licensed in the state where the pharmacy is located; the statute does not require a Florida-licensed manager. §465.0158 separately requires a nonresident sterile compounding permit to ship compounded sterile products into Florida. That permit requires an owner/PIC attestation, USP <797> policies, and a home-state inspection report no older than 6 months (initial) or 1 year (renewal); otherwise the Department inspects at the applicant's cost or accepts an approved entity's or an FDA inspection report.

The Board may exempt isolated transactions (§465.0156(2)). Internet pharmacies permitted under §465.0197 are handled separately. Last statutory amendment to §465.0156 was in 2022 (ch. 2022-35).

May a 503A (traditional) pharmacy dispense or distribute compounded preparations to a practitioner for office use (administration in the office, not patient-specific)? The federal position is that 503A requires patient-specific prescriptions; this is what the state pharmacy act and board rules allow.

Fla. Admin. Code R. 64B16-27.700(3) lets a pharmacist dispense compounded drugs to a veterinarian for office use, subject to quantity limits, a written agreement, records retrievable within 72 hours, and a 'Compounded Drug' label. For human-use products, subsection (4) states that compounding practices 'such as patient-specific, anticipatory, office stock or office use' must strictly adhere to federal law, including 21 U.S.C. 353a and 353b. The rule gives no separate state authorization for 503A office stock for human patients. Under FDA's interpretation, 503A compounding requires a patient-specific prescription, so non-patient-specific office stock comes through 503B outsourcing facilities. The Florida Board of Pharmacy (Department of Health) enforces the rule.

The rule was amended three times between 2025 and 2026 (effective 4-9-25, 3-10-26 and 8-3-26). The Board's notices describe the 2025-2026 changes as removing 'unnecessary' or 'outdated' language. The 'no' answer reflects the rule's deference to federal law as FDA reads it; the rule itself does not use the word 'prohibited'. Florida sources that predate 2025 may describe different office-use terms.

Does the state require an FDA-registered 503B outsourcing facility located outside the state to hold a state license/registration (as an outsourcing facility, nonresident manufacturer, wholesaler or pharmacy) before shipping into the state?

Fla. Stat. §465.0158(1) requires a nonresident sterile compounding permit before 'an outsourcing facility' may ship, mail, deliver or dispense compounded sterile products into Florida. §465.003 defines an outsourcing facility as an FDA-registered 503B location where sterile compounding occurs. A 503B that is not a pharmacy submits proof of FDA outsourcing registration and its home-state license or permit in place of nonresident pharmacy registration. It also submits cGMP-compliant policies and a current inspection report (6 months old for initial, 1 year for renewal; FDA inspection reports may be accepted). The statute does not address non-sterile products from 503Bs. Separately, §499.01(2)(c) requires a nonresident prescription drug manufacturer permit (DBPR) for out-of-state manufacturers distributing prescription drugs in Florida. Ch. 499 defines 'manufacture' to include compounding and excludes only pharmacies.

Whether DBPR (Division of Drugs, Devices and Cosmetics) requires a ch. 499 nonresident manufacturer permit of 503B outsourcing facilities was not confirmed. §465.0158 history: ch. 2014-148, ch. 2016-224.

Has the state signed FDA's standard Memorandum of Understanding Addressing Certain Distributions of Compounded Human Drug Products (October 2020)? If not, FD&C Act §503A limits its 503A pharmacies' out-of-state distribution to 5% of total prescription orders (currently not enforced by FDA pending rulemaking).

Signing the standard MOU means the state board agrees to investigate complaints about compounded drugs its 503A pharmacies ship out of state and to identify and report to FDA pharmacies that distribute "inordinate amounts" interstate (more than 50% of their compounded prescriptions); in exchange, the statutory 5% out-of-state cap in FD&C Act §503A(b)(3)(B) does not apply to that state's pharmacies. FDA lists only Colorado, Kentucky and New Hampshire as signatories; Florida is not among them. For a non-signing state, FD&C Act §503A(b)(3)(B)(ii) caps a 503A pharmacy's out-of-state distribution of compounded drugs at 5% of its total prescription orders. FDA now considers the October 2020 standard MOU suspended (it does not expect signatory states to carry out MOU activities and will not sign new ones) and is not enforcing the 5% limit until a final rule and an updated MOU are published; FDA's rulemaking (RIN 0910-AI71) listed a proposed rule for 11/2026 in the Fall 2025 Unified Agenda.

The FDA list of signed MOUs (current as of 2023-01-23) is older than 2 years, but FDA stopped entering new agreements under the 2020 MOU in October 2022, so no state can have signed since. The FDA "Compounding Information for States" page (current as of 2026-08-28) still describes the MOU as awaiting rulemaking. Pending: FDA proposed rule on 503A distribution (RIN 0910-AI71, NPRM projected 11/2026); H.R. 5316 (introduced 2025-09-11, referred to House Energy & Commerce) would remove the MOU provision from §503A.

Besides DEA registration, does the state require practitioners to hold a separate state controlled substance registration, license or permit to prescribe, administer or dispense controlled substances (e.g. testosterone, Schedule III)? "Conditional" means a state registration is needed only in some settings, such as keeping controlled-substance stock in the office.

Fla. Stat. 893.02 defines 'practitioner' as a physician, osteopathic physician, APRN, PA and other listed licensees 'provided such practitioner holds a valid federal controlled substance registry number' - no state CS registration is required. A practitioner who dispenses drugs for a fee must register with their board as a dispensing practitioner (fee up to $100, renewed with the license) and follow pharmacy rules (Fla. Stat. 465.0276(2)). A registered dispensing practitioner may not dispense a Schedule II or Schedule III controlled substance except samples, surgical procedures (Schedule III up to a 14-day supply), approved clinical trials, opioid-treatment programs and a few other listed settings (465.0276(1)(b)); in-office administration is not dispensing.

Key for testosterone (Schedule III): a Florida office cannot dispense take-home testosterone under the dispensing-practitioner registration except under the listed exceptions; prescribing and in-office administration are unaffected. Florida also requires E-FORCSE (PDMP) use; pain-management clinics register separately (not researched here).

Must a prescriber query the state Prescription Drug Monitoring Program before prescribing, and does the mandate cover Schedule III drugs such as testosterone? "Yes" means a mandate that reaches Schedule III; "conditional" means a mandate limited to certain drugs (e.g. opioids or benzodiazepines) or situations; "no" means no prescriber query mandate.

Fla. Stat. 893.055(8) requires a prescriber or dispenser (or designee) to consult the PDMP before prescribing or dispensing a controlled substance for a patient age 16 or older; 'controlled substance' means Schedules II-V and 'dispenser' includes a dispensing health care practitioner. Exceptions: nonopioid Schedule V drugs, hospice patients, and system outages (in which case the reason must be documented and no more than a 3-day supply may be prescribed or dispensed). The duty is triggered by prescribing or dispensing; in-office 'administration' is defined separately and is not listed as a trigger. The Department of Health issues a nondisciplinary citation for a first offense; later offenses are subject to discipline.

Frequency: every prescription/dispensing (no periodic interval). Testosterone (C-III) is caught for both prescribing and physician dispensing. Section history includes a 2026 amendment (s. 167, ch. 2026-168); the mandate text read is from the 2026 Florida Statutes. PDMP TTAC also lists board rules 64B8-9.0181 and 64B15-14.0131 (not reviewed).

May physicians dispense prescription drugs (not just administer them) directly to patients from their practice? "Yes" means allowed under standard rules (labeling, records, and at most a simple notice to the board); "conditional" means a separate dispensing registration, permit or license, or quantity, day-supply or drug-category limits; "no" means prohibited except narrow exceptions.

Fla. Stat. 465.0276 requires a practitioner who dispenses medicinal drugs for a fee to register with the professional licensing board as a dispensing practitioner (fee up to $100). A registered practitioner may not dispense Schedule II or Schedule III controlled substances, except free samples, dispensing in connection with surgery (Schedule III up to 14 days), approved clinical trials, Department of Corrections, and FDA-approved opioid-addiction treatment. Before dispensing, the practitioner must give a written prescription and advise the patient it may be filled in the office or at any pharmacy, and must label non-manufacturer packages. Complimentary samples dispensed without remuneration need no registration.

Read from the 2025 Florida Statutes edition on flsenate.gov (last amended by ch. 2018-13). Practical effect: testosterone (C-III) generally cannot be dispensed from a Florida office; it can be administered in office or prescribed to a pharmacy.

For a patient located in the state: must the prescriber hold this state's license (or a telehealth registration or special license), is an in-person exam required before prescribing (generally or for controlled substances), are there state limits on prescribing Schedule III drugs such as testosterone by telehealth, and is the state an Interstate Medical Licensure Compact member? "Yes" means a state license and the in-person standard of care apply (opioid-only or Schedule II-only limits are described but do not change the answer); "conditional" means extra state conditions such as a telehealth registration route, an in-person exam requirement, controlled-substance limits reaching Schedule III, or registration of telehealth businesses. Federal DEA rules apply on top.

A clinician not licensed in Florida may treat Florida patients by telehealth after registering with the applicable board as a telehealth provider; registrants need liability coverage and may not open a Florida office or provide in-person care (Fla. Stat. 456.47). If the evaluation is sufficient to diagnose and treat, no prior physical exam or record review is required. Telehealth providers may not prescribe Schedule II controlled substances except for psychiatric disorders, inpatient hospital care, hospice or nursing-home residents; the statute places no telehealth-specific limit on Schedule III drugs such as testosterone. IMLC: member.

Read from the 2025 Florida Statutes edition (created 2019, amended 2020, 2022, 2023). Florida joined the IMLC through CS/SB 7016 (IMLC map dated 12/20/2024).

Who may administer botulinum toxin and dermal fillers (physicians, PAs, NPs, RNs, LPNs, estheticians, dentists), under what supervision (on-site vs available), and must a physician/NP/PA perform a prior good-faith exam?

Florida's Nurse Practice Act defines professional nursing to include administering medications and treatments as prescribed or authorized by a duly licensed practitioner, and practical nursing as administering treatments and medications under the direction of an RN or a physician, osteopathic physician, podiatrist or dentist. No Board of Medicine or Board of Nursing rule or FAQ specific to botulinum toxin or dermal fillers was found (both boards' FAQ databases were searched on 2026-09-23). Botox and fillers remain prescription products, so a licensed prescriber's order or authorization is required.

Answer rests on general RN scope, not an aesthetics-specific rule. '2026 Florida Statutes' recorded as 2026-07-01 (usual effective date). A secondary blog cited a 2023 Florida Board of Nursing declaratory statement on RN injections that could not be located.

What does the state require for elective IV hydration/vitamin (incl. NAD+) therapy: who may start IVs, is a patient-specific order or good-faith exam required before a patient's first IV, are standing orders allowed, and are there rules for mobile IV services?

Florida's Nurse Practice Act allows RNs to administer medications and treatments as prescribed or authorized by a licensed practitioner, and LPNs to do so under RN or physician direction. Searches of the Board of Medicine and Board of Nursing FAQ databases (2026-09-23) returned no IV-hydration guidance, unlike many other states. Clinics that are not wholly owned by licensed practitioners generally need an AHCA health care clinic licence (see CPOM), and mobile clinics fall within the clinic definition.

No Florida IV-hydration statement located; Florida Board of Nursing rules on LPN IV therapy education (reported as a 30-hour course) were not fetched. Admixing vitamins into IV bags may raise Board of Pharmacy compounding issues.

Does the state enforce the corporate practice of medicine doctrine (non-physicians may not own medical practices or employ physicians), and how does that affect med spa ownership?

Under the Health Care Clinic Act, a 'clinic' is an entity that provides health care services and tenders charges for them (including mobile clinics). Entities wholly owned by licensed health care practitioners, or by a practitioner plus close family where the practitioner supervises the business, are exempt. A licensed clinic must have a medical director who is a physician (or a licensed practitioner whose scope covers the services if no physician services are offered). Permit Health lists Florida as 'Permitted (with conditions)' and MedPath as 'No (clinic license)'.

Exemptions in §400.9905 are detailed; check with AHCA whether a cash-only med spa model is exempt.

Who may perform laser/IPL/RF aesthetic procedures (laser hair removal, resurfacing): physicians only, delegated to RNs/PAs, or licensed electrologists/estheticians/laser technicians with state certification?

Board of Medicine rule 64B8-56.002 allows an electrologist to use laser or light-based devices for hair removal only after specified laser training plus a certification exam (SCMHR or a Board-approved exam), under a properly trained supervising physician who may supervise on premises or by telehealth from within 150 miles, with no more than four electrologists per physician. The initial consultation must include an examination by a physician, and written protocols, semi-annual inspections and emergency training are required. The Board's FAQ says this is the only regulation directly addressing laser hair removal; other delegation of cosmetic laser work falls under general physician delegation rules. Laser devices must be registered with the DOH Bureau of Radiation Control.

Rule last amended 2021 (over two years old, possibly stale) but current per flrules.org on 2026-09-23. FAQ entries on laser registration were updated 2026-01-21.

Does the state license clinical laboratories itself, beyond federal CLIA certification, including out-of-state labs that test specimens from the state?

The current Florida Statutes chapter 483 contains only Part I (Clinical Laboratory Personnel, ss. 483.800-483.828), Part II (Medical Physicists) and Part III (Genetic Counseling); facility-licensure provisions no longer appear in the chapter. AHCA's Laboratory Licensing Unit is Florida's CLIA state agency. Technologists and lab directors working in Florida need Florida personnel licenses.

The date the facility-licensure part was repealed was not confirmed here. Personnel licensure still applies to Florida-based labs.

May consumers order their own lab tests without a practitioner order (direct access testing)? A practitioner-ordered panel is always fine; this matters for take-home and consumer test kits.

ADLM (formerly AACC) reported in 2019 that 37 states and DC let consumers order some or all tests directly, but it did not publish the state list, and this research did not confirm Florida's rule. Florida's lab regulator (CLIA state agency) is Florida Agency for Health Care Administration, Laboratory Licensing Unit (LABSTAFF@ahca.myflorida.com, 850-412-4500). The question matters for take-home and consumer test kits, not for panels a clinician orders.

A commercial 2026 guide (Just Labs) groups Florida with states that have their own frameworks. Florida's clinical-laboratory facility statute no longer appears in ch. 483 (only personnel licensure remains). Not confirmed. The ADLM figure dates from 2019 (older than 2 years).

Has the state enacted a law or rule specifically about stem cell, exosome or regenerative-medicine therapies (notice/disclosure duties, permission for certain non-FDA-approved uses, or Right to Try extensions covering them)?

CS/CS/SB 1768 (ch. 2025-185) created §458.3245 (MDs) and a parallel section for DOs. 'Stem cell therapy' means treatment using afterbirth placental perinatal stem cells or HCT/Ps, excluding cells derived from a fetus or embryo after an abortion. Cells must be retrieved, manufactured and stored in an FDA-registered facility that is certified by a listed body (e.g., AATB, AABB, WMDA, NMDP), and a post-thaw viability analysis is required. Ads must carry a mandated notice ('THIS NOTICE MUST BE PROVIDED TO YOU UNDER FLORIDA LAW...') in type no smaller than the largest used, and a signed consent must cover FDA status, anticipated results, risks and alternatives. Violations are grounds for discipline; willfully performing prohibited treatments is a third-degree felony. Federal FDA rules still apply regardless of state law: stem cell, birth-tissue and exosome products are regulated by FDA, and a state law cannot make an unapproved biologic FDA-approved.

Physicians only: NPs and PAs are not authorized. Pending: CS/SB 1092 (2026) would extend similar authority to podiatric physicians, effective July 1, 2026 if enacted; its final status was not confirmed. The DO section number is from secondary sources.

Does the state have cosmetic or sunscreen requirements beyond federal MoCRA, such as ingredient bans (PFAS, formaldehyde, phthalates), ingredient reporting, sunscreen-ingredient bans, or bans on selling animal-tested cosmetics?

Florida does not appear on 2026 compilations of state PFAS-in-cosmetics laws, on the list of states banning animal-tested cosmetics, or among the jurisdictions with sunscreen-ingredient bans. Federal MoCRA and FDA rules on cosmetics and OTC sunscreens still apply. Other state laws that touch cosmetics generally, such as state food-drug-cosmetic acts or consumer-protection laws, were not surveyed.

Florida has no state cosmetic ingredient law, but a 2020 state law (SB 172) bars local governments from regulating OTC drugs and cosmetics. That preempted Key West's planned oxybenzone/octinoxate sunscreen ban. The animal-testing list is Wikipedia's 'as of 2023' compilation (older than 2 years); effective dates were not confirmed.